Has previously received Dapsone therapy.
The subject or any of their healthcare providers is aware of the subjects HLA type.
Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobin reductase deficiency
Satisfies any contraindications or restrictions to Dapsone therapy as listed in the product labels.
Current severe illness, including heart, liver and renal failure, major organ allograft, malignancy requiring parenteral chemotherapy that can not be discontinued for the duration of the trial, or any other conditions which, in the opinion of the Investigator, would make the patient unsuitable for the study.
Any laboratory abnormality at Screening which, in the opinion of the Investigator, should preclude the subject's participation in the study [alanine aminotransferase (ALT), glutamic oxaloacetic transaminase(ALT), et al).
Pregnant women or women who are breastfeeding.
Subject is, in the opinion of the Investigator, unable to complete the 6 week Observation period and the EPT assessments as required.
A positive result for HLA-B*1301 in those subjects randomised to the genetic screening arm.

NCT02550080_exc_T1
Drug
Dapsone
NCT02550080_exc_T3
Condition
Glucose-6-phosphate dehydrogenase deficiency
NCT02550080_exc_T4
Condition
methemoglobin reductase deficiency
NCT02550080_exc_T5
Condition
contraindications
NCT02550080_exc_T6
Drug
Dapsone
NCT02550080_exc_T7
Condition
renal failure
NCT02550080_exc_T8
Condition
r and ure, ma
NCT02550080_exc_T9
Condition
t, li ure, ma
NCT02550080_exc_T10
Condition
major organ allograft
NCT02550080_exc_T11
Condition
malignancy
NCT02550080_exc_T12
Procedure
chemotherapy
NCT02550080_exc_T16
Measurement
HLA-B*1301
NCT02550080_exc_T17
Value
positive